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FRI0501 CARDIOVASCULAR DISEASE RISK ASSESSMENT IN 
PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER 
RELATED AMYLOIDOSIS
M. Romano1, M. Yilmaz2, B. Jackson3, C. Acikel4, D. Piskin3, R. Berard3, 
E. Demirkaya3. 1Istituto Ortopedico Gaetano Pini, Milan, Italy; 2Epigenetic 
Health Solutions, Ankara, Turkey; 3Western University, London, Canada; 4Clinical 
Research International, Cologne, Germany
Background: FMF is an autosomal recessive disorder. Systemic inflammation 
in autoinflammatory disorders cause secondary systemic AA amyloidosis, which 
has been suggested as an important contributing factor to the excess cardiovas-
cular disease (CVD) risk in patients with FMF.
Objectives: Our aim was to investigate the CVD-related clinical outcomes in 
patients with FMF-related amyloidosis and to define risk factors for CVD events 
(CVDEs).
Methods: A cross-sectional evaluation with prospective follow-up of consec-
utive patients with FMF-related amyloidosis or other non-diabetic primary glo-
merulonephropathy (PGN) was performed. Patients were followed for CVDEs. 
Flow-mediated dilatation (FMD), FGF-23 levels, serum lipid levels, hsCRP, BMI 
and homeostasis model assessment (HOMA) were assessed. A Cox regression 
analysis was performed to evaluate the probability of CVDEs associated with 
each risk factor.
Results: There were 107 patients in FMF-related amyloidosis group and 126 
patients with PGN group. Forty-seven CVDEs were registered during the 4.2-
years follow up; all 28 patients in the FMF-related amyloidosis versus 14/19 
patients with PGN group who developed CVDEs before 40 years of age (P=0.002) 
(Figure  1). CVD mortality was 2.8 times higher (95% CI 1.02-7.76, p=0.03) in 
patients with FMF-related amyloidosis (n=12) than PGN (n=5). Mortality due to 
CVD was higher in patients less than 40 years old with amyloidosis than PGN 
(12/107 and 3/126 respectively, RR=4.71, 95% CI 1.36-16.25, p=0.006). Patients 
with CVDEs had higher levels of proteinuria, hsCRP and FGF23, and lower FMD 
compared to patients without CVDEs. Across both groups, FGF23 and FMD lev-
els were independently associated with the risk of CVDEs (Table 1).
Conclusion: Patients with FMF-related amyloidosis are at increased risk of 
CVDEs with early mortality age. These patients should be closely monitored and 
if inflammation is poorly controlled with colchicine, biological agents must be 
added to treatment even if they develop amyloidosis. We also found that hsCRP, 
FGF 23 and FMD levels were the strongest predictors of CVD risk in patients with 
FMF. These biomarkers can stratify risk of early CVD in patients with FMF-related 
amyloidosis.
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FRI0502 SEASONAL CLUSTERING OF ACUTE SARCOIDOSIS 
IN GERMANY AND ASSOCIATIONS WITH AIR 
POLLUTION
P. Rustler1, D. Schindler2, R. Voll1, F. Kollert3. 1Division of Rheumatology 
and Clinical Immunology, Department of Internal Medicine, University 
Medical Center Freiburg, Freiburg, Germany; 2Environmental Meteorology, 
University of Freiburg, Freiburg, Germany; 3Department of Rheumatology, 
Immunology & Allergology (RIA), Inselspital, University Hospital Bern, Bern, 
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Background: Sarcoidosis is a multisystemic granulomatous disorder of unknown 
origin. The central role of macrophages and granuloma formation, the predom-
inant involvement of lung and skin, and certain risk populations (e.g. firefight-
ers1, 2) might be explained by causative airborne antigen(s)3. Whether air pollution 
is involved in pathogenesis and seasonal clustering of sarcoidosis is uncertain.
Objectives: This study has been set to analyze seasonal clustering of acute sar-
coidosis and associations to air pollution.
Methods: Patients with acute sarcoidosis, defined by bihilar lymphadenopa-
thy, ankle swelling, and/or erythema nodosum plus physician’s diagnosis,were 
included in this retrospective study. Disease onset (seasonal clustering) and 
associations to air pollution (particulate matter (PM
10
) and nitrogen dixoide (NO
2
)) 
were analyzed. Google Trends queries were conducted to address seasonal clus-
tering on a global scale.
Results: A total of 185 patients with acute sarcoidosis were included; 48.7 % of 
the enrolled patients were female and Löfgren triad was complete in 73.5 % of 
patients. Acute sarcoidosis clustered from December to June in West Germany 
(p<0.005, Kendall τ=-0.68), peaking in January (17.8 % of cases) and in the 
first third of the year (54.5 %). Mean PM
10
 values clustered from December to 
April with values between 15 and 40 µg/m3. NO
2
 levels were measured high-
est from November to March (45 µg/m3) and lowest between April and August 




) were associated with 
higher monthly incidence rates of acute sarcoidosis (Cross correlation coeffi-
cient ranging between 0.7 -0.8). Google Trends analysis yielded seasonal clus-
tering (p<0.005, Kendall τ = -0.64) in winter and spring months on the northern 
hemisphere.
Conclusion: In Central Europe acute sarcoidosis peaks in winter and spring 




 maxima are reached. 
Whether components of particulate matter might be involved in the pathogenesis 
of sarcoidosis has to be elucidated by further studies.
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A MULTI-CENTER RETROSPECTIVE STUDY BY 
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Figure 1. Comparison of cardiovascular disease survival between patients with FMF-related 
amyloidosis or primary glomerulopathy.
Table 1. Multivariate analysis of factors associated with the risk of suffer-
ing a cardiovascular event
  B HR 95.0% CI for 
Exp(B)
p
 Variables   Lower Upper  
All Groups FGF23 .033 1.034 1.017 1.051 <.001
 FMD -.946 .388 .262 .575 <.001
Primary FGF23 .050 1.051 1.019 1.084 .002
glomerulopathy FMD -.651 .522 .300 .908 .021
Amyloidosis FGF23 .034 1.035 1.012 1.058 .003
 FMD -1.531 .216 .109 .430 <.001
 hsCRP -.040 .961 .915 1.009 .108
FMD, Flow-mediated dilatation; hsCRP, high sensitivity C reactive protein; CI, Confidence 
interval
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